Back to OGNView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in In Vitro Fertilization
View Full LandscapeDrug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA1/25/2010
Elonva
Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an Assisted Reproductive Technology (ART) program. Elonva is indicated for the treatment of adolescent males (14 to less than 18 years and older) with hypogonadotropic hypogonadism, in combination with human Chorionic Gonadotropin (hCG).
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
A-Phase: tirofiban; Z-Phase simvastatinPhase 3
Acute Coronary Syndrome
Tibolone 2.5 mgPhase 3
Postmenopausal Women
MK0217, alendronate sodium / Duration of Treatment : 2 YearsPhase 3
Osteoporosis, Postmenopausal
MK0663, Etoricoxib / Duration of Treatment : 12 WeeksPhase 3
Recurrent Low Back Pain
Radiopaque ImplanonPhase 3
Contraception
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts